Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective

Overview of attention for article published in Clinical Therapeutics, February 2017

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 5,630 followers.

Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal… https://t.co/JdAXpAVy25

Comment on Capri S (2017): Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally https://t.co/56TEF0JLK6

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity.